Corporate, Microbial Genomics

Illumina statement on novel coronavirus

Illumina has enacted precautionary measures focusing on the health and safety of our employees, families, customers and communities

Illumina statement on novel coronavirus
17 March 2020

With the global spread of SARS-CoV-2, Illumina has enacted precautionary measures focusing on the health and safety of our employees, families, customers and communities. To help protect Illumina employees and business continuity, we have proactively implemented efforts including limiting travel and attendance at meetings and conferences, and allowing employees to work remotely, where possible. We are closely monitoring the situation and will update our action plan to protect employees, keep customers running and support efforts to minimize the spread of the virus. To date, we have not experienced sustained supply chain or other operational delays. We will continue to monitor and update as the situation evolves, balancing the safety of our employees and the needs of our customers. 

 

 

Recent Articles

Inside a Mumbai lab using genomics for tuberculosis surveillance
Inside a Mumbai lab using genomics for tuberculosis surveillance
Fighting drug-resistant tuberculosis in South Africa
Fighting drug-resistant tuberculosis in South Africa
Children’s Mercy Kansas City tackles the unique complexity of pediatric cancer
Children’s Mercy Kansas City tackles the unique complexity of pediatric cancer